Ranitidine Hydrochloride (ranitidine + hydrochloride)

Distribution by Scientific Domains


Selected Abstracts


Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Issue 4 2009
Shouko Ono
Abstract Background and Aim:, Histamine 2 receptor antagonists and proton-pump inhibitors, drugs that are widely used for the treatment of acid-related diseases, have different clinical characteristics. The objective of this study was to compare the acid-suppressing effects of ranitidine hydrochloride and those of rabeprazole sodium at the first administration and re-administration after withdrawal. Methods:, The study was designed as an open-label, randomized, two-way cross-over trial. Seven Helicobacter pylori -negative healthy volunteers were enrolled in this study. Ranitidine hydrochloride (300 mg/day) or rabeprazole sodium (20 mg/day) was administered from days 1 to 7 and from days 11 to 13. The percentage of time with gastric pH < 4 and the median gastric pH were evaluated for 15 consecutive days by a Bravo capsule fixed to the stomach. Results:, On day 1, there was no significant difference between the acid-suppressing effects of the two drugs (ranitidine vs rabeprazole: not significant). Although rabeprazole sodium maintained a potent and stable effect from days 2 to 7 (ranitidine vs rabeprazole: P < 0.05), the effect of ranitidine hydrochloride was attenuated after day 4. In addition, the effect of ranitidine hydrochloride at re-administration was attenuated (days 11, 12, and 13 vs pre-administration: not significant). Conclusion:, In view of our observations, we expect symptoms associated with gastric acidity to be more adequately controlled with rabeprazole sodium in the short term when compared to ranitidine hydrochloride. [source]


Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride,

JOURNAL OF PHARMACEUTICAL SCIENCES, Issue 8 2005
H. Kortejärvi
Abstract Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence testing for the approval of immediate release (IR) solid oral dosage forms containing ranitidine hydrochloride are reviewed. According to the current Biopharmaceutics Classification System (BCS), ranitidine hydrochloride should be assigned to Class III. However, based on its therapeutic and therapeutic index, pharmacokinetic properties and data related to the possibility of excipient interactions, a biowaiver can be recommended for IR solid oral dosage forms that are rapidly dissolving and contain only those excipients as reported in this study. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 94:1617,1625, 2005 [source]


Highly Sensitive Electrogenerated Chemiluminescence Detecting Ranitidine Based On Chemically Modifying Microenvironment of the Chemiluminescence Reaction

ELECTROANALYSIS, Issue 11 2005
Xingwang Zheng
Abstract Using a graphite electrode modified with vaseline and NiO, ranitidine showed a strongly ECL enhancing effect for the weak ECL signal of electrooxidation of luminol. Based on this finding, a more sensitive ECL method for ranitidine was firstly proposed. Under the optimum experimental conditions, the ranitidine hydrochloride concentration in the range of 3.0×10,8,9.0×10,6,mol/L was proportional to the enhancing ECL signal and offered a 9×10,9,mol/L detection limit for ranitidine hydrochloride. At the same time, based on the investigation on this ECL reaction mechanism, a new concept, to improve the suitable ECL reaction micro-environment with chemically modified electrode technique for the better analytical performances of ECL analysis was also firstly proposed. [source]


Immediate acid-suppressing effects of ranitidine hydrochloride and rabeprazole sodium following initial administration and reintroduction: A randomized, cross-over study using wireless pH monitoring capsules

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Issue 4 2009
Shouko Ono
Abstract Background and Aim:, Histamine 2 receptor antagonists and proton-pump inhibitors, drugs that are widely used for the treatment of acid-related diseases, have different clinical characteristics. The objective of this study was to compare the acid-suppressing effects of ranitidine hydrochloride and those of rabeprazole sodium at the first administration and re-administration after withdrawal. Methods:, The study was designed as an open-label, randomized, two-way cross-over trial. Seven Helicobacter pylori -negative healthy volunteers were enrolled in this study. Ranitidine hydrochloride (300 mg/day) or rabeprazole sodium (20 mg/day) was administered from days 1 to 7 and from days 11 to 13. The percentage of time with gastric pH < 4 and the median gastric pH were evaluated for 15 consecutive days by a Bravo capsule fixed to the stomach. Results:, On day 1, there was no significant difference between the acid-suppressing effects of the two drugs (ranitidine vs rabeprazole: not significant). Although rabeprazole sodium maintained a potent and stable effect from days 2 to 7 (ranitidine vs rabeprazole: P < 0.05), the effect of ranitidine hydrochloride was attenuated after day 4. In addition, the effect of ranitidine hydrochloride at re-administration was attenuated (days 11, 12, and 13 vs pre-administration: not significant). Conclusion:, In view of our observations, we expect symptoms associated with gastric acidity to be more adequately controlled with rabeprazole sodium in the short term when compared to ranitidine hydrochloride. [source]


Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride,

JOURNAL OF PHARMACEUTICAL SCIENCES, Issue 8 2005
H. Kortejärvi
Abstract Literature and experimental data relevant to the decision to allow a waiver of in vivo bioequivalence testing for the approval of immediate release (IR) solid oral dosage forms containing ranitidine hydrochloride are reviewed. According to the current Biopharmaceutics Classification System (BCS), ranitidine hydrochloride should be assigned to Class III. However, based on its therapeutic and therapeutic index, pharmacokinetic properties and data related to the possibility of excipient interactions, a biowaiver can be recommended for IR solid oral dosage forms that are rapidly dissolving and contain only those excipients as reported in this study. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 94:1617,1625, 2005 [source]